Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FM8HF
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $6,849
Award facts
- Contract value 100% obligated
- $6,848.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $6,848.92 to DMS Pharmaceutical Group Inc. for the supply of XOLAIR 300 mg/2 ml auto-injector units. XOLAIR (omalizumab) is a biologic medication used to treat moderate-to-severe allergic asthma and other allergic conditions, making this a critical pharmaceutical supply for military healthcare facilities. The delivery order was awarded on August 12, 2025, with an ultimate completion date of September 3, 2025, and will be fulfilled from the vendor's location in Park Ridge, Illinois. This award does not utilize a set-aside designation.
This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 and extending through November 2026. DMS Pharmaceutical Group is a woman-owned small business and established pharmaceutical wholesaler that has served as a strategic supplier within the federal pharmaceutical supply chain since 2001. The company's IDC with the Defense Logistics Agency enables the issuance of firm fixed-price delivery orders for a comprehensive portfolio of pharmaceutical products supporting Department of Defense healthcare sites worldwide, encompassing prescription medications, biologics, vaccines, and specialized auto-injectors such as this XOLAIR order.
Quick answers
Who was awarded contract SPE2DB25FM8HF?
SPE2DB25FM8HF was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 12, 2025.
How much is contract SPE2DB25FM8HF worth?
The government has obligated $6,849 on SPE2DB25FM8HF.
Is contract SPE2DB25FM8HF an order under another contract?
Yes. SPE2DB25FM8HF is a delivery order under SPE2DB22D9151, an indefinite delivery contract.
Was contract SPE2DB25FM8HF competed?
The extent of competition for SPE2DB25FM8HF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award